The stock of CorMedix Inc (CRMD) has gone down by -2.17% for the week, with a 9.12% rise in the past month and a -10.51% drop in the past quarter. The volatility ratio for the week is 5.80%, and the volatility levels for the past 30 days are 5.44% for CRMD. The simple moving average for the past 20 days is 3.17% for CRMD’s stock, with a 15.90% simple moving average for the past 200 days.
Is It Worth Investing in CorMedix Inc (NASDAQ: CRMD) Right Now?
The 36-month beta value for CRMD is at 1.59. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CRMD is 53.95M, and currently, shorts hold a 19.20% of that float. The average trading volume for CRMD on July 30, 2024 was 504.04K shares.
CRMD) stock’s latest price update
CorMedix Inc (NASDAQ: CRMD)’s stock price has gone rise by 0.96 in comparison to its previous close of 4.68, however, the company has experienced a -2.17% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-07-03 that BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath® (taurolidine and heparin) to outpatient dialysis centers and vascular access clinics where patients receive outpatient dialysis and catheter placement services. The outpatient launch coincides with the effective date of July 1st for outpatient reimbursement of DefenCath as directed by the Center for Medicare & Medicaid Services (CMS).
Analysts’ Opinion of CRMD
Many brokerage firms have already submitted their reports for CRMD stocks, with RBC Capital Mkts repeating the rating for CRMD by listing it as a “Outperform.” The predicted price for CRMD in the upcoming period, according to RBC Capital Mkts is $6 based on the research report published on August 10, 2023 of the previous year 2023.
Needham, on the other hand, stated in their research note that they expect to see CRMD reach a price target of $31. The rating they have provided for CRMD stocks is “Buy” according to the report published on February 17th, 2021.
JMP Securities gave a rating of “Mkt Outperform” to CRMD, setting the target price at $22 in the report published on September 29th of the previous year.
CRMD Trading at -0.91% from the 50-Day Moving Average
After a stumble in the market that brought CRMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.50% of loss for the given period.
Volatility was left at 5.44%, however, over the last 30 days, the volatility rate increased by 5.80%, as shares surge +13.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.73% lower at present.
During the last 5 trading sessions, CRMD rose by +0.41%, which changed the moving average for the period of 200-days by +41.40% in comparison to the 20-day moving average, which settled at $4.61. In addition, CorMedix Inc saw 25.66% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRMD starting from Todisco Joseph, who purchase 13,561 shares at the price of $3.74 back on Mar 13 ’24. After this action, Todisco Joseph now owns 352,839 shares of CorMedix Inc, valued at $50,718 using the latest closing price.
DUNTON ALAN W, the Director of CorMedix Inc, purchase 3,000 shares at $3.30 during a trade that took place back on Dec 15 ’23, which means that DUNTON ALAN W is holding 15,250 shares at $9,900 based on the most recent closing price.
Stock Fundamentals for CRMD
Current profitability levels for the company are sitting at:
- -179.69 for the present operating margin
- -2.2 for the gross margin
The net margin for CorMedix Inc stands at -165.2. The total capital return value is set at -0.93. Equity return is now at value -89.76, with -78.96 for asset returns.
Based on CorMedix Inc (CRMD), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -71.79. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1545.6.
Currently, EBITDA for the company is -48.75 million with net debt to EBITDA at 0.64. When we switch over and look at the enterprise to sales, we see a ratio of 746.38. The receivables turnover for the company is 304110.0for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.65.
Conclusion
In conclusion, CorMedix Inc (CRMD) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
